NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Koman.


You said:

And that logic of the first 33patients in this trial making the analysis longer doesn't fly- I'd expect the opposite because that group should have shown efficacy for PFS and OS by now allowing the DMC to comfortably continue the trial since everyone will get DC-VAXL eventually IF the current data supports efficacy.

--Koman


That's not what LongUSA is saying. He is saying that the analysis would take longer if they are comparing the 33 statistically to themselves (placebo v. experimental), to the latter group (post January 2011), and to the entire group. This would take added time, thought and discussion, because it infrequently comes up for statisticians, DMC, sponsors, and others.